Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company specializing in novel therapeutics for degenerative retinal diseases, will participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025.
The company's executive management team will deliver two presentations: an on-demand corporate presentation at 7:00 AM ET and participate in a panel discussion on "Pivotal-Stage Assets for Retinal Disorders" at 11:00 AM ET. Both presentations will be accessible via webcast through Belite Bio's investor relations website, with replays available for 90 days.
Belite Bio (NASDAQ: BLTE), un'azienda in fase clinica specializzata nello sviluppo di farmaci innovativi per le malattie degenerative della retina, parteciperà alla Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright il 13 agosto 2025.
Il team di gestione esecutiva dell'azienda terrà due presentazioni: una presentazione aziendale on-demand alle 7:00 ET e parteciperà a un panel di discussione su "Asset in fase cruciale per i disturbi retinici" alle 11:00 ET. Entrambe le presentazioni saranno accessibili in webcast tramite il sito web delle relazioni con gli investitori di Belite Bio, con repliche disponibili per 90 giorni.
Belite Bio (NASDAQ: BLTE), una empresa en etapa clínica especializada en el desarrollo de terapias novedosas para enfermedades degenerativas de la retina, participará en la Conferencia Virtual Anual de Oftalmología H.C. Wainwright el 13 de agosto de 2025.
El equipo ejecutivo de la compañía realizará dos presentaciones: una presentación corporativa bajo demanda a las 7:00 AM ET y participará en un panel de discusión sobre "Activos en etapa pivotal para trastornos retinianos" a las 11:00 AM ET. Ambas presentaciones estarán disponibles vía webcast a través del sitio web de relaciones con inversionistas de Belite Bio, con repeticiones accesibles por 90 días.
Belite Bio (NASDAQ: BLTE)는 퇴행성 망막 질환을 위한 혁신 치료제를 전문으로 하는 임상 단계 신약 개발 회사로, 2025년 8월 13일 H.C. Wainwright 연례 안과 가상 컨퍼런스에 참여합니다.
회사의 경영진은 두 차례 발표를 진행합니다: 동영상 주문형 기업 발표는 동부시간 오전 7시에 진행되며, 오전 11시에는 "망막 질환을 위한 중추 단계 자산"에 관한 패널 토론에 참여합니다. 두 발표 모두 Belite Bio 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 다시보기는 90일간 가능합니다.
Belite Bio (NASDAQ : BLTE), une société en phase clinique spécialisée dans le développement de traitements innovants pour les maladies dégénératives de la rétine, participera à la Conférence virtuelle annuelle d'ophtalmologie H.C. Wainwright le 13 août 2025.
L'équipe de direction de l'entreprise présentera deux interventions : une présentation d'entreprise à la demande à 7h00 ET et participera à un panel de discussion sur les "Actifs en phase pivotale pour les troubles rétiniens" à 11h00 ET. Les deux présentations seront accessibles en webcast via le site des relations investisseurs de Belite Bio, avec des rediffusions disponibles pendant 90 jours.
Belite Bio (NASDAQ: BLTE), ein klinisch fortgeschrittenes Unternehmen, das sich auf neuartige Therapeutika für degenerative Netzhauterkrankungen spezialisiert hat, wird an der H.C. Wainwright Jahreskonferenz für Ophthalmologie am 13. August 2025 teilnehmen.
Das Führungsteam des Unternehmens wird zwei Präsentationen halten: eine On-Demand-Unternehmenspräsentation um 7:00 Uhr ET und die Teilnahme an einer Podiumsdiskussion zum Thema "Pivotal-Stage Assets für Netzhauterkrankungen" um 11:00 Uhr ET. Beide Präsentationen sind über einen Webcast auf der Investor-Relations-Website von Belite Bio zugänglich, mit Wiedergaben für 90 Tage.
- None.
- None.
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows:
- 7:00 am ET, on-demand corporate presentation
- 11:00 am ET, “Pivotal-Stage Assets for Retinal Disorders” panel discussion
Webcast Link Instructions
A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) presenting at the H.C. Wainwright Ophthalmology Conference 2025?
Where can I watch Belite Bio's (BLTE) H.C. Wainwright conference presentations?
What topics will Belite Bio (BLTE) discuss at the H.C. Wainwright conference?
How long will Belite Bio's (BLTE) conference presentations be available for replay?
